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ABSTRACT
Recent studies have shown that anaerobes account for 0.5–9% of all episodes of bacteraemia in
hospitalised patients, with variations according to geographical location and demographic characteristics,
most notably age, but few data are available for cancer patients. This study investigated retrospectively
the incidence of anaerobic bacteraemia in cancer patients who received non-surgical treatment over a
6-year period at a tertiary oncology centre. Gastrointestinal (27%) and haematological (29%) malignancies
were the most common underlying diseases. Among 45 isolates of anaerobic bacteria recovered from 45
patients, Bacteroides spp. and Clostridium spp. were the most frequent pathogens (60% and 22%,
respectively). Twenty episodes of bacteraemia were polymicrobial, most frequently with aerobic Gram-
negative bacilli (18 cases). The mortality rate for patients with adequate antimicrobial therapy from the
outset was 14%, compared with 63% for patients who were not treated adequately at any time.
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INTRODUCTION
Anaerobic bacteraemia is uncommon, accounting
for 0.5–9% of all positive blood cultures in
hospitals [1]. The effectiveness of antimicrobial
therapy in improving outcomes for patients with
anaerobic bacteraemia has been challenged, and a
vital role for surgery has been suggested [2,3], but
several studies have shown that anaerobic bac-
teraemia is often missed on the basis of clinical
findings, and that many patients receive inad-
equate antimicrobial treatment until blood culture
results are available [4,5]. In immunosuppressed
patients, although bacteraemia is usually caused
by aerobic or facultative bacteria [6], anaerobic
bacteria comprise most of the endogenous micro-
bial flora and can also cause bacteraemia. The
mucosal and visceral damage caused by cancer
chemotherapy increases the risk of bacteraemia
related to endogenous anaerobes.
The objectives of the present study were: to
evaluate the incidence and clinical significance of
anaerobic bacteraemia, as documented by blood
cultures, in cancer patients; to investigate man-
agement changes in response to microbiology
laboratory reports of anaerobic bacteraemia; and
to evaluate the impact of antimicrobial therapy on
patient survival.
PATIENTS AND METHODS
Setting
The Gustave Roussy Institute is a 400-bed tertiary-care
teaching hospital in the Paris area, France, which treats only
patients with solid or haematological malignancies. There are
111 medical beds, 155 surgical beds, 35 paediatric beds, 15
intensive care unit beds and 38 other beds.
Patients and definitions
Patients with blood cultures positive for anaerobic bacteria
between 1993 and 1998 were identified retrospectively from
the microbiology laboratory database. An infectious diseases
specialist and a microbiologist reviewed the hospital charts of
each patient, abstracting data regarding age, gender, underly-
ing disease, chronic health according to the criteria of McCabe
and Jackson [7], dates of blood culture sampling, dates that
blood culture reports were available to clinicians, dates and
nature of antimicrobial therapy, body sites positive for anaer-
obic bacteria, and patient mortality. The definition of focus of
infection was based on clinical data, confirmed, whenever
possible, by microbiological results.
Corresponding author and reprint requests: J.-R. Zahar,
Service de Microbiologie-Hygie`ne, CHU Necker, Enfants-
malades, 149 rue de Se`vres, 75007 Paris, France
E-mail: jean-ralph.zahar@nck.ap-hop-paris.fr
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
Pneumonia was defined as the presence of new chest
infiltrates, combined with at least one of the major criteria of
cough, sputum production or history of fever (‡ 38.5C), or
two or more of the minor criteria of dyspnoea, pleuritic
chest pain or pulmonary consolidation on clinical examina-
tion, and, when available, a microbiological sample. Urinary
tract infection was defined as the presence of urinary
symptoms suggesting urinary tract infection, combined with
a history of fever (‡ 38.5C) and a positive urine culture with
a single microorganism (‡ 105 CFU ⁄mL). Mucositis was
considered when patients with risk-factors (i.e., intensive
chemotherapy) had local signs of mucositis corresponding to
grade 4 or 5 of the WHO oral toxicity scale. Gastrointestinal
infection was considered when clinical features were in
agreement with the diagnosis of gastrointestinal infection
and no other focus of infection was suspected. Gynaecolo-
gical infection was defined as clinical features in agreement
with a diagnosis of salpingitis. Cellulitis was defined as
clinical signs of superficial skin infection. Abscess was
defined as a purulent collection, combined with a positive
microbiological sample.
Underlying diseases were identified based on the descrip-
tion given by the physician in the medical records. A patient
was considered to have heart or liver disease if such a
condition was documented as ongoing at the time of the
positive blood culture. Shock was defined as presence of any of
the following: a sustained (> 1 h) systolic blood pressure
decrease of at least 40 mm Hg from baseline; systolic blood
pressure < 90 mm Hg after adequate volume replacement; or
a need for vasopressors. Hospital-acquired bacteraemia was
defined as the occurrence of new symptoms of infection and
the onset of bacteraemia ‡ 48 h after hospital admission.
Positive blood cultures were considered to be clinically
significant when two or more consecutive cultures were
positive for the same organism, or when a single blood culture
was positive in a patient who had fever (> 38.5C) and a
documented focus of infection at the time of blood sample
collection. Propionibacterium isolates were considered to be
contaminants when found in a single blood culture. Antimi-
crobial treatment was deemed adequate when the microor-
ganism was susceptible in vitro [8]. None of the patients
required surgery for the anaerobic infection.
Cultures and susceptibility testing
Each blood sample was inoculated into aerobic and anaerobic
blood culture bottles (Vital-duo; bio-Me´rieux, Marcy l’Etoile,
France) and incubated for 5 days in the automated Vital
System (bio-Me´rieux). All bottles showing bacterial growth
were subcultured on to agar plates and incubated under both
aerobic and anaerobic conditions, and bacteria were then
identified by conventional methods [9]. Antibiotic susceptibil-
ity testing was performed by agar disk-diffusion, with isolates
classified as susceptible, intermediate or resistant according to
the guidelines of the Comite´ de l’Antibiogramme de la Socie´te´
Franc¸aise de Microbiologie [10].
Statistical analysis
Results were expressed as medians with 95% CIs. Categorical
variables were compared using the chi-square test (or Fisher’s
exact test where appropriate). Continuous variables were
compared using the Wilcoxon rank sum test for unpaired
data. Data were analysed by Epi-Info (Centers for Disease
Control, Atlanta, GA, USA). All tests were two-sided, and
p values < 0.05 were considered significant.
RESULTS
During the 6-year study period (1993–1998),
117 834 blood cultures were performed in the
hospital; of these, 7989 (6.8%) yielded bacteria.
Blood cultures from 46 cancer patients grew
anaerobic bacteria (0.6% of all positive blood
cultures); however, one patient had a single
positive blood culture for Propionibacterium acnes,
leaving 45 patients for the study.
Patient characteristics
Of the 45 patients (median age 48 years; range
38–75 years) included in the study, 18 (40%) were
female. The underlying diseases are summarised
in Table 1; 32 (71%) patients had solid tumours
and 13 (29%) had haematological malignancies.
Chemotherapy had partially failed in 44 patients,
and 14 had a recent history of metastatic disease
or leukaemia relapse. Administration of chemo-
therapy within the last 30 days was recorded for
27 (60%) patients, and 19 (42%) were receiving
corticosteroid therapy with a daily dosage
> 1 mg ⁄kg. None of the 45 patients received
antimicrobial agents within the 2-week period
preceding the episode of anaerobic bacteraemia.
The median time between the preceding course of
chemotherapy and the episode of bacteraemia
was 17 days (8–26 days).
All 45 patients were admitted with a fever,
usually > 39C, to a ward or to the intensive care
unit for suspected acute infection. On the day of
Table 1. Underlying malignancy in 45 cancer patients
with anaerobic bacteraemia
Underlying disease No. of cases
Haematological disease 13
Non-Hodgkin lymphoma 5
Burkitt lymphoma 2
Hodgkin lymphoma 2
Acute lymphocytic leukaemia 2
Acute myelocytic leukaemia 2
Solid tumours 32
Bone 1
Breast 5
Gastrointestinal 12
Gynaecological 5
Pulmonary 4
Urinary tract 2
Mediastinal 2
Laryngeal 1
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the blood sample yielding the first culture
positive for anaerobes, 17 (38%) patients had
neutropenia (< 1000 neutrophils ⁄lL), while the
remaining 28 patients had leukocytosis.
Microbiological findings
Approximately two-thirds of the cases of anaer-
obic bacteraemia were caused either by Bacteroides
spp. (27 ⁄ 45; 60%), mainly Bacteroides fragilis
(14 ⁄ 45; 31%), or by Gram-positive anaerobes
(14 ⁄ 45; 31%), mainly Clostridium perfringens
(7 ⁄ 45; 16%) (Table 2). For 20 patients, the blood
cultures grew more than one microorganism.
Escherichia coli was the microorganism found
most commonly in combination with an anaerobe
(13 ⁄ 45; 29%) (Table 3). Table 4 lists the presumed
and confirmed sites of infection with anaerobic
bacteria. The focus of infection was presumed in
24 cases, proven in 13 cases and unknown in eight
cases. The gastrointestinal tract was the most
common presumed source of anaerobic bacterae-
mia (22 ⁄ 45; 49%), followed by oral mucositis
(7 ⁄ 45; 16%), cellulitis and abscesses (3 ⁄ 45), gynae-
cological infections (2 ⁄ 45), pneumonia (1 ⁄ 45),
urinary tract infection (1 ⁄ 45), and pharyngeal
abscess (1 ⁄ 45).
Antimicrobial therapy
As infection was the reason for admission, empir-
ical antimicrobial therapy was usually started at
admission (43 ⁄ 45; 96%). A single antimicrobial
agent was given to eight patients, two antimicro-
bial agents to 28 patients, and three antimicrobial
agents to seven patients. Ceftazidime was the
empirical antimicrobial agent used most com-
monly at admission (29% of patients). Only 13
(29%) patients received adequate antimicrobial
treatment, comprising two patients who received
amoxycillin–clavulanic acid alone, seven who
received amoxycillin–clavulanic acid and ciprofl-
oxacin, and four who received an ureidopenicillin
and either an aminoglycoside (two patients) or
ciprofloxacin (two patients). However, aminopen-
icillins, with or without b-lactamase inhibitors,
carbapenems and metronidazole were all active
against these anaerobic isolates.
Among the remaining 32 patients, 16 were
switched to adequate antimicrobial agents after
blood culture results were obtained, but 16
patients remained on inadequate antimicrobial
therapy throughout the course of their infection.
Mortality
The overall hospital mortality was 42% (19
patients), with a median time from the blood
Table 2. Pathogens identified in 45 cancer patients with
anaerobic bacteraemia
Pathogens No. of cases
Gram-negative bacilli 30
Bacteroides fragilis 14
Bacteroides uniformis 2
Bacteroides vulgatus 3
Bacteroides ovatus 2
Bacteroides distasonis 3
Bacteroides thetaiotaomicron 2
Bacteroides ruminicola 1
Prevotella oralis 2
Fusobacterium necrophorum 1
Gram-positive bacilli 14
Clostridium perfringens 7
Clostridium septicum 3
Bifidobacterium 3
Lactobacillus 1
Gram-negative cocci 1
Veillonella 1
Table 3. Pathogens recovered from blood cultures in
addition to anaerobic bacteria (20 patients)
Pathogens No of cases
Gram-negative bacilli 18
Escherichia coli 13
Klebsiella pneumoniae 1
Enterobacter cloacae 1
Hafnia alvei 1
Acinetobacter spp. 1
Morganella morganii 1
Gram-positive cocci 6
Staphylococcus aureus 2
Streptococcus spp. 2
Enterococcus spp. 2
Yeast 2
Candida spp. 2
Table 4. Source of anaerobic bacteraemia in 45 cancer
patients
Source No. of cases
Gastrointestinal tract 22
Biliary tract 6
Diverticulitis 4
Tumour necrosisa 7
Hepatic metastasis 3
Abdominal 1
Other site 3
Enteritis 3
Bowel obstruction 2
Mucositis 7
Pharyngeal abscessa 1
Gynaecological 2
Pneumoniaa 1
Skina 3
Abscess 1
Cellulitis 2
Urinary tract infectiona 1
Unknown 8
aConfirmed by microbiological data.
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culture result to death of 4.5 days (3–16 days). Of
these 19 patients, none were deemed terminally
ill, and therefore none had care withdrawn. The
median time to death after the last positive blood
culture was 2 days (4–8 days). The mortality rate
was not influenced by age, underlying disease,
source of infection, or whether infection was
polymicrobial and nosocomial. The mortality rate
was 63% (ten patients) in the group that never
received adequate antimicrobial treatment, 47%
(seven patients) in the group that was switched to
adequate antimicrobial therapy when the blood
culture result became available, and 14% (two
patients) in the group that received adequate
antimicrobial therapy from the outset. Immediate
adequate antimicrobial therapy was significantly
protective against mortality (Table 5). Compared
to the group that received adequate therapy from
the outset, the increased mortality in the group
that never received adequate therapy was statis-
tically significant, but the increased mortality in
the group switched to adequate therapy was not.
DISCUSSION
Anaerobic bacteraemia is fairly rare in hospital-
ised patients [3]. However, cancer patients are at
high risk for bacterial infection because intensive
cancer therapy regimens cause both profound
granulocytopenia and disruption of physical bar-
riers [11]. An increase in the incidence of anaer-
obic bloodstream infections has been reported in
patients with cancer [12] and in bone marrow
transplant recipients [13]. Mucositis has been
identified as a risk-factor for bloodstream infec-
tion caused by a variety of microorganisms
[14,15]. Other known risk-factors for anaerobic
bloodstream infection include haematological
malignancies and a history of prophylactic ther-
apy with quinolones, surgery, or broad-spectrum
antimicrobial therapy [12].
In the present study, anaerobes accounted for
only 0.6% of all positive blood cultures from
hospitalised cancer patients, in accordance with
previous reports [3]. The spectrum of causative
agents and the sources of infection were also
consistent with previous data [16]. Bacteroides spp.
were the most common isolates, followed by
Gram-positive anaerobes. Lactobacillus and Bifido-
bacterium, usually considered to be contaminants,
caused severe infections in some of these cancer
patients. The gastrointestinal tract was the most
common source of bacteraemia, both in the
present study and in previous studies of non-
surgical patients [2,16].
Whereas anaerobes comprise most of the
endogenous microflora and can cause bacterae-
mia when mucosal or visceral damage facilitates
Table 5. Clinical characteristics of
45 patients with anaerobic bacterae-
mia
All
(n = 45)
Survived
(n = 26)
Died
(n = 19)
Odds
ratio 95% CI p value
Female gender, n (%) 18 (40) 10 (56) 8 (44) 1.16 0.29–4.61 0.95
Male gender, n (%) 27 (60) 16 (60) 11 (40) 0.86 0.22–3.40 0.95
Age mean (years) 56 (43–56) 50 (38–59) 47 (33–64) 0.72
Shock at admission, n (%) 3 (7) 0 3 (16%) 0.07
Acute renal failure, n (%) 15 (33) 7 (27) 8 (42) 1.97 0.47–8.4 0.45
McCabe score at admission, n (%)
A 6 (13) 3 (11) 3 (16) 1.44 0.20–10.6 0.68
B 31 (69) 19 (73) 12 (63) 0.63 0.15–2.69 0.70
C 8 (18) 4 (15) 4 (21) 1.47 0.25–8.6 0.70
Underlying malignancy, n (%)
Solid tumour 32 (71) 19 (52) 13 (48) 0.8 0.18–3.52 0.99
Haematological malignancy 13 (29) 7 (54) 6 (46) 1.25 0.28–5.53 0.9
Co-morbidities, n (%)
Steroids 19 (42) 11 (58) 8 (42) 0.99 0.25–3.88 0.77
Underlying disease, n (%)
Heart disease 7 (15) 3 (11) 4 (21) 2.04 0.32–13.86 0.43
Lung disease 6 (13) 2 (8) 4 (8) 3.20 0.42–29.2 0.49
Polymicrobial infection, n (%) 18 (40) 12 (46) 6 (32) 0.54 0.13–2.18 0.56
Leukocyte count (means) · 109 ⁄L 4.6 (0.3–27.6) 8.2 (0.5–12.7) 1.16 0.34–3.98 0.78
Neutropenia, n (%)
< 1000 (· 109 ⁄L) 17 (38) 10 (38) 07 (37) 0.93 0.23–3.75 0.84
£ 500 (· 109 ⁄L) 15 (33) 09 (35) 06 (31) 0.87 0.217–3.65 0.91
Nosocomial acquisition, n (%) 20 (44) 08 (31) 12 (63) 3.86 0.94–16.57 0.06
Antimicrobial therapy, n (%)
Immediate adequate treatment 14 (31) 12 (86) 2 (14) 0.14 0.02–0.83 0.02
Delayed adequate treatment 15 (33) 8 (53) 7 (47) 1.31 0.32–5.48 0.91
Either immediate or delayed treatment 29 (64) 20 (65) 9 (35) 0.27 0.06–1.15 0.08
Inadequate treatment throughout 16 (36) 6 (37) 10 (63) 3.70 0.87–16.51 0.08
CI, confidence interval.
Zahar et al. Anaerobic bacteraemia in cancer patients 727
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 724–729
their entry into the bloodstream [17], most data
regarding anaerobic bacteraemia come from sur-
gical patients. In contrast, the present study
focused on anaerobic bacteraemia in non-surgical
cancer patients, with or without neutropenia.
Importantly, most of these patients had haemato-
logical disease or abdominal cancer. The intensive
chemotherapy regimens required to treat haema-
tological malignancies, and the damage to the gut
mucosa associated with abdominal cancers, may
increase the risk of translocation of anaerobes to
the bloodstream [17]. In neutropenic patients, the
number of reported anaerobic bloodstream infec-
tions has increased in recent years [18,19]. Among
the neutropenic patients in the present study,
many had chemotherapy-induced oral mucositis
[20] or periodontal disease. Together with the
types of anaerobe recovered from these neutro-
penic patients, this suggests an oral source of
infection in a number of cases. Disruption of the
mucosal barrier, and antibiotic-related selection
pressure on the oral flora in patients with neu-
tropenia, probably facilitate the occurrence of
anaerobic bacteraemia.
The overall mortality in the present study was
high (42%), but consistent with previous studies
[21]. In keeping with other studies [16], many of
these patients did not receive antimicrobial agents
active against the anaerobes recovered from their
blood cultures. Only one-third of patients
received adequate antimicrobial treatment before
the blood culture results were available, and
38% of patients never received adequate anti-
microbial agents. Early adequate antimicrobial
therapy is the cornerstone of treatment for
acquired infections. Empirical antimicrobial ther-
apy consists of selecting agents effective against
the pathogens most likely to be responsible for
the clinically suspected infection. Early adminis-
tration of antimicrobial agents active against the
microorganisms responsible for severe infections
in hospitalised patients is essential; inadequate
antimicrobial therapy affected outcomes
adversely in patients with pneumonia, perito-
nitis, bacteraemia or meningitis [22,23]. Inade-
quate antimicrobial treatment in critically-ill
patients with bloodstream infections has been
associated with a higher rate of hospital mortal-
ity, compared with the rate in patients who
received adequate treatment [24]. In the present
study, adequate antibiotic therapy was the only
factor associated with better survival; thus,
survival was not dependent on underlying dis-
ease, source of infection, or the recovery of more
than one organism [25]. However, these factors
were uncommon among the participants in the
present study, and consequently the statistical
power for identifying them as risk-factors was
limited.
Most cases of bacteraemia in cancer patients
are caused by facultative Gram-negative bacilli
and Gram-positive cocci. Few studies have
focused on the role of bacteraemia caused by
strict anaerobes in cancer patients [16,21],
although several risk-factors for anaerobic infec-
tions exist in this population. Given the high
mortality associated with anaerobic bacteraemia
in cancer patients, the present study confirms the
opinion of Patel et al. [14] that anaerobic infec-
tion should be considered when selecting initial
antimicrobial agents for febrile cancer patients,
with or without neutropenia, most notably those
with oral mucositis or a history of invasive
procedures on the gastrointestinal tract. Anaer-
obic blood cultures should be performed rou-
tinely in these patients, as the results may help
to correct the choice of antimicrobial agents
when the initial regimen does not include drugs
active against anaerobes. However, clinicians
must bear in mind the side-effects of antibiotics
that are active against anaerobes. In several
studies, exposure to these antibiotics was corre-
lated significantly with colonisation and infection
by vancomycin-resistant enterococci. Moreover,
studies have shown that antibiotics active against
anaerobes promote intestinal overgrowth of
nosocomial pathogens [26–28].
In conclusion, the present study showed that
anaerobic bacteraemia in cancer patients was
associated with intra-abdominal tumours and
haematological malignancies. Pathogen distribu-
tion was the same as for non-cancer patients.
Empirical antimicrobial regimens were not con-
sistently effective against anaerobes. Effective
antimicrobial therapy from the outset was associ-
ated with a higher survival rate. Patients with
abdominal cancer or haematological malignancies
and evidence of acute infection should be given
empirical antimicrobial agents active against
anaerobes. Furthermore, anaerobe growth in a
blood culture should be considered clinically
important, as failure to give adequate treatment
for aerobic bacteraemia may seriously decrease a
patient’s chance of survival.
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